Avalo Therapeutics (AVTX) Shares Outstanding (Diluted Average) (2015 - 2026)
Avalo Therapeutics posted quarterly Shares Outstanding (Diluted Average) of $20.1 million for Q1 2026, up 91.22% year-on-year from $10.5 million in Q1 2025, and up 50.0% on a QoQ basis from $13.4 million in Q4 2025.
Avalo Therapeutics (AVTX) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $20.1 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 91.22% year-over-year to $20.1 million; the trailing twelve-month figure through Mar 2026 stood at $20.1 million (up 91.22% YoY), and the FY2025 full-year result was $13.4 million, up 78.82% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $20.1 million, up from $13.4 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $20.1 million in Q1 2026 and bottomed at $859381.0 in Q1 2024.
- The 3-year median for Shares Outstanding (Diluted Average) is $10.5 million (2025), against an average of $10.1 million.
- Peak annual rise in Shares Outstanding (Diluted Average) reached 1123.54% in 2025, while the deepest fall reached 39.46% in 2025.
- A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $7.5 million in 2024, then surged by 78.82% to $13.4 million in 2025, then jumped by 50.0% to $20.1 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $20.1 million (Q1 2026), $13.4 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 20.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.11 Mn |
| Dec 31, 2025 | 13.40 Mn |
| Sep 30, 2025 | 14.00 Mn |
| Jun 30, 2025 | 10.67 Mn |
| Mar 31, 2025 | 10.51 Mn |
| Dec 31, 2024 | 7.50 Mn |
| Sep 30, 2024 | 6.54 Mn |
| Jun 30, 2024 | 7.65 Mn |
| Mar 31, 2024 | 859,381.00 |
| Dec 31, 2018 | 34.77 Mn |
| Sep 30, 2018 | 34.65 Mn |
| Dec 31, 2017 | 18.75 Mn |
| Sep 30, 2017 | 14.96 Mn |
| Dec 31, 2016 | 8.83 Mn |
| Sep 30, 2016 | 8.76 Mn |
| Dec 31, 2015 | 2.23 Mn |